88 - Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial

Presenting Author(s)

• 

  Deepa B. Gotur, MD, FCCP, FCCM (she/her/hers)

  Associate Professor Clinical Medicine
  Weill Cornell Medical College and Houston Methodist Hospital
  Houston, TX, United States

  Slides

Co-Author(s)

• AM

  Anuj Malik, MD, MS

  Ascension St. John's Medical Center
  Tulsa, Oklahoma, United States
• VM

  Vadim Markovtsov, PhD

  Rigel Pharmaceuticals, Inc.
  South San Francisco, California, United States
• LY

  Lucy Yan, MD, PhD (he/him/his)

  VP, Clinical Development
  Rigel Pharmaceuticals
  South San Francisco, California, United States
• WD

  Wolfgang Dummer, MD, PhD

  Rigel Pharmaceuticals
  South San Francisco, California, United States
• 

  Ziad Mallat, MD, PhD

  Professor of Cardiovascular Medicine
  University of Cambridge
  Cambridge, England, United Kingdom